UNSPSC 51171950: Molfarnate

This classification denotes an anti-ulcer agent with the molecular formula C31H50O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5288I2K01S, chemically known as 3,7,11-trimethyl-2,6,10-dodecatrienyl 4,8,12-trimethyl-3,7,11-tridecatrienoate. but generally known as molfarnate, which bears US NIH Compound Identifier 6446651. European Medicines Agency schedules Molfarnate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09039MIG. The term MOLFARNATE is an International Non-Proprietary Name.

UNSPSC 51171950 Molfarnate (Commodity) represents pharmaceutical and pharmacy-related services that state and local governments are actively procuring, though the code's nominal label obscures the concrete work being solicited. Recent opportunities show state and local buyers acquiring drug-testing services, direct-to-manufacturer prescription program administration, and multi-source generic pharmaceuticals and over-the-counter products through cooperative purchasing vehicles. The issuing bodies span county community supervision departments, state health and human services commissions, and multi-state cooperative purchasing alliances. Work under this code ranges from specimen collection and lab-certified drug screening with immunoassay and confirmatory testing (LC/MS/MS or GC/MS), to pharmacy benefit program design and direct-contracting logistics, to bulk pharmaceutical distribution through authorized wholesaler networks.

Recent activity is concentrated in Texas and Minnesota. Collin County Community Supervision and Corrections Department posted an RFP on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services covering two Plano and McKinney collection sites with approximately 25,031 annual tests and an estimated contract value of $600,000 over two years with three optional one-year renewals. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—an exploratory phase preceding formal solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with awarded vendors taking effect July 1, 2026 and a two-year contract term. Evaluation in the Collin County opportunity weights vendor understanding and firm qualifications at 55 percent combined, with cost at 30 percent; MMCAP weights price competitiveness at 75 percent. No recent opportunities reveal activity outside the Southwest and Upper Midwest.